Immuneering Corp. (IMRX) announced positive initial response data from the first five patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first line pancreatic cancer as part of its ongoing Phase 2a clinical trial.IMRX closed Thursday's regular trading at $1.43 up $0.14 or 10.85%.

作为其正在进行的2a期临床试验的一部分，Immuneering Corp.（IMRX）宣布了IMM-1-104联合改良吉西他滨/纳布紫杉醇治疗一线胰腺癌的前五名患者的阳性初始反应数据。IMRX周四的常规交易收于1.43美元，上涨0.14美元，涨幅10.85%。

In the after-hours trading, the stock further gained $0.79 or 55.24%.According to the company, the first two patients in the Phase 2a arm evaluating IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer have recorded complete or partial responses for an initial response rate of 40% (2/5) and disease control rate of 80% (4/5), with the other three patients earlier in the course of treatment and all five continuing on treatment.The company noted that the Benchmarks for gemcitabine/nab-paclitaxel alone in first-line pancreatic cancer patients were established by the Phase 3 MPACT study, which included 1 Complete Response (CR) out of 431 patients, a 23% Overall Response Rate, and a 48% Disease Control Rate1.

在盘后交易中，该股进一步上涨0.79美元，涨幅55.24%。据该公司称，在一线胰腺癌中使用改良吉西他滨/纳布紫杉醇评估IMM-1-104的2a期患者中，前两名患者的初始缓解率为40%（2/5），疾病控制率为80%（4/5），其他三名患者在治疗过程中较早，所有五名患者均继续治疗。该公司指出，第三阶段MPACT研究确定了一线胰腺癌患者单独使用吉西他滨/纳布紫杉醇的基准，其中431例患者中有1例完全缓解（CR），总缓解率为23%，疾病控制率为48%1。

Benchmarks for modified (m) Gemcitabine/nab-Paclitaxel include an 18.6% ORR2..

改良（m）吉西他滨/nab-紫杉醇的基准包括18.6%的ORR2。。

The company said the combination of IMM-1-104 plus modified gemcitabine/nab-paclitaxel was observed to be well tolerated, with an emerging safety profile in line with known data for both therapeutics respectively.The trial's Data and Safety Monitoring Board (DSMB) has approved enrolling additional patients into this arm at 320mg QD p.o., the first of which have already been dosed and are awaiting first scans.For More Such Health News, visit rttnews.com.

该公司表示，观察到IMM-1-104加改良吉西他滨/nab-紫杉醇的组合具有良好的耐受性，并且新出现的安全性分别与两种疗法的已知数据一致。该试验的数据和安全监测委员会（DSMB）已批准以每日一次320mg的剂量将更多患者纳入该组，其中第一批患者已经服用，正在等待首次扫描。欲了解更多此类健康新闻，请访问rttnews.com。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局决定生物技术股